Emcure Pharmaceuticals

Emcure Pharmaceuticals

1,372.70
+2.00
(0.15%)
Market Cap
26,013.81 Cr
EPS
36.43
PE Ratio
34.45
Dividend Yield
0.22 %
Industry
Healthcare
52 Week High
1,580.00
52 Week Low
889.00
PB Ratio
5.84
Debt to Equity
0.45
Add Ratio
hide

Investment Returns

In Long Term
In Short Term
1 Year
0.00%
2 Years
0.00%
3 Years
0.00%
4 Years
0.00%
5 Years
0.00%
Analyst Rating
- By Refinitiv from4 analysts
BUY
Analysts have suggested that investors can buy this stock
Buy
Buy+75.00 %
+75.00 %
Hold
Hold+25.00 %
+25.00 %
Sell
Sell0.0 %
0.0 %

Company News

View All News
Caret
positive
Emcure Pharmaceuticals Approves Incorporation of Wholly-Owned Subsidiary Emcure Wellness18 hours ago
Emcure Pharmaceuticals' Board of Directors approved the incorporation of a wholly-owned subsidiary named Emcure Wellness Private Limited in Pune, Maharashtra. The new entity will have an authorized share capital of Rs. 10 crores and initial paid-up capital of Rs. 1 lakh. The subsidiary will operate in the pharmaceuticals industry to manufacture, promote, sell and distribute pharmaceuticals and related products. Emcure will subscribe to 100% of the initial share capital through cash consideration at face value of Rs. 10 per share.
positive
Emcure Pharmaceuticals announced its quarterly results with consolidated revenue from operations reaching Rs 1,815 crore, up 16.6% year-over-year. The company achieved EBITDA of Rs 360 crore with margins at 19.8%, representing a 15.8% increase. Profit after tax stood at Rs 153 crore, up 8.2% compared to the previous year. The domestic business contributed Rs 909 crore (14% growth) while international operations generated Rs 906 crore (19.5% growth). North America showed particularly strong performance with 72.3% growth, while Europe grew 8.6%. The company's domestic growth was supported by its distribution partnership for Sanofi's cardiovascular brands, which are now fully integrated. Emcure maintains its position as the 12th largest pharma company in India and operates in over 70 countries globally.
Competitors
LTP
Market Cap (₹ Cr.)
P/E Ratio
Revenue (₹ Cr.)
YoY Revenue Growth %
Net Profit (₹ Cr.)
YoY Profit Growth %
RSI
1,593.60
#1 3,82,358.02
33.10
#1 54,729.00
9.71
#1 10,980
-19.84
39.45
6,009.00
1,59,520.07
70.63
9,712.00
18.67
2,191
26.74
43.85
1,553.40
1,25,469.33
23.63
28,409.50
7.12
5,291
9.88
57.67
3,579.10
1,21,133.01
60.27
11,539.40
6.99
1,911
19.91
51.53
1,268.10
1,05,831.96
#1 18.41
33,741.20
16.73
5,725
1.26
48.40
2,550.60
1,05,270.59
56.03
12,744.20
#1 20.90
2,007
-18.14
55.83
1,013.85
1,02,017.03
21.84
23,511.00
18.55
4,615
2.60
60.44
1,943.90
88,777.03
23.95
22,909.50
13.74
3,306
#1 51.64
50.97
31,150.00
66,191.58
47.11
6,684.70
9.64
1,414
11.55
45.41
5,333.50
63,769.99
27.89
13,458.30
3.70
2,216
21.39
57.64
Forecast
Actual
Growth Rate
Revenue Growth
18.67 %
Net Income Growth
34.10 %
Cash Flow Change
-22.38 %
ROE
-9.82 %
ROCE
-1.72 %
EBITDA Margin (Avg.)
0.99 %

Quarterly Financial Results

Quarterly Financials
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Mar 2025
Jun 2025
Revenue
1,571
1,664
1,697
1,783
1,839
2,038
1,959
2,121
2,104
Expenses
1,261
1,337
1,381
1,460
1,479
1,621
1,601
1,724
1,687
EBITDA
311
327
316
323
360
417
359
397
417
Operating Profit %
19 %
20 %
17 %
18 %
19 %
19 %
18 %
19 %
20 %
Depreciation
67
70
84
91
94
97
97
97
100
Interest
52
59
61
66
59
46
32
39
27
Profit Before Tax
191
198
171
167
207
273
230
261
291
Tax
50
52
51
46
55
72
74
63
76
Net Profit
141
146
120
121
153
202
156
197
215
EPS in ₹
7.21
7.70
6.27
6.36
7.95
10.23
8.12
9.97
10.92

Balance Sheet

Balance Sheet
2018
2019
2020
2021
2022
2023
2024
2025
Total Assets
5,247
5,644
6,004
6,807
6,064
6,673
7,806
8,233
Fixed Assets
2,049
2,247
2,382
2,188
2,044
2,147
3,125
3,197
Current Assets
2,335
2,453
2,703
3,718
3,424
3,836
4,260
4,556
Capital Work in Progress
531
581
485
302
320
411
159
177
Investments
0
0
0
0
25
25
318
95
Other Assets
2,667
2,817
3,137
4,318
3,674
4,089
4,204
4,763
Total Liabilities
5,247
5,644
6,004
6,807
6,064
6,673
7,806
8,233
Current Liabilities
2,336
2,543
2,920
3,408
2,965
3,019
3,211
2,668
Non Current Liabilities
1,157
1,201
1,100
1,031
985
1,004
1,474
923
Total Equity
1,755
1,900
1,984
2,368
2,114
2,650
3,122
4,642
Reserve & Surplus
1,520
1,654
1,731
2,092
1,807
2,320
2,771
4,257
Share Capital
181
181
181
181
181
181
181
190

Cash Flow

Cash Flow
2019
2020
2021
2022
2023
2024
2025
Net Cash Flow
-700
32
259
42
134
219
-58
Investing Activities
-409
-168
-257
-575
-468
-715
-96
Operating Activities
444
500
704
768
747
1,097
852
Financing Activities
-735
-301
-189
-152
-145
-164
-814

Share Holding

% Holding
Jul 2024
Sept 2024
Dec 2024
Mar 2025
Jun 2025
Promoter
78.08 %
78.08 %
77.94 %
77.92 %
77.91 %
FIIs
1.76 %
2.91 %
3.05 %
3.07 %
2.86 %
DIIs
3.34 %
3.96 %
3.87 %
3.44 %
2.84 %
Government
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
Public / Retail
7.73 %
5.00 %
5.14 %
5.51 %
5.95 %
Others
9.10 %
10.04 %
10.00 %
10.06 %
10.44 %
No of Share Holders
4,98,006
1,52,914
1,43,449
1,39,671
1,33,549

Dividend History

Dividends per share (FY)
Dividend yield (FY) %
Dividends per share (FY)
Dividend yield (FY) %
Annual Cash Flows 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Dividend Per Share (₹) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 2 3
Dividend Yield (%) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.19 0.22

Corporate Action

Record Date Corporate Action Information Announcement Day LTP at Annoucement LTP at Record Day
07 Nov 2024 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
07 Nov 2024 1,406.40 1,444.25
06 Feb 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
06 Feb 2025 1,345.75 1,249.80
22 May 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
22 May 2025 1,036.35 1,073.60
07 Aug 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
07 Aug 2025 1,405.55 1,421.25
14 Aug 2025 DIVIDEND Dividend
₹ 3.00 /share
14 Aug 2025 1,073.60 1,453.80
28 Aug 2025 ANNUAL GENERAL MEETING Annual General Meeting
NA
28 Aug 2025 1,408.15 1,468.60

Announcements

Update On Re-Appointment Of Dr. Mukund Gurjar As A Whole-Time Director And Appointment Of Secretarial Auditor Of The Company.8 days ago
Shareholder Meeting / Postal Ballot-Scrutinizers Report8 days ago
Shareholder Meeting / Postal Ballot-Outcome of AGM9 days ago
Announcement under Regulation 30 (LODR)-Earnings Call TranscriptAug 13, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 08, 2025
Intimation Under Regulation 30 And 36(1)(B) Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 About Dispatch Of Letters To The Members Whose E-Mail Addresses Are Not Registered With The Company/ Depository Participants.Aug 07, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeAug 07, 2025
Outcome Of The Board Meeting Held On August 07 2025 To Approve The Unaudited Financial Results (Consolidated And Standalone) For The Quarter Ended June 30 2025Aug 07, 2025
Board Meeting Outcome for Outcome Of Board Meeting Held On August 07 2025Aug 07, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 03, 2025
Intimation Of Notice Of The 44Th Annual General Meeting Of Emcure Pharmaceuticals Limited To Be Held On Thursday August 28 2025Aug 02, 2025
Reg. 34 (1) Annual Report.Aug 02, 2025
Intimation Of The 44Th AGM And Record Date For Final Dividend For The Financial Year Ended March 31 2025.Aug 01, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJul 28, 2025
Board Meeting Intimation for Approval Of Unaudited Financial Results (Standalone And Consolidated) For The Quarter Ended June 30 2025.Jul 28, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJul 16, 2025
Announcement under Regulation 30 (LODR)-Change in ManagementJul 14, 2025
Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 (SEBI Listing Regulations) - US FDA Inspection At Our Manufacturing Facility (Oncology) Located At Sanand Ahmedabad Gujarat India.Jul 09, 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jul 09, 2025
Announcement under Regulation 30 (LODR)-Updates on AcquisitionJul 04, 2025
Closure of Trading WindowJun 25, 2025
Intimation Under Regulation 31A Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 - Submission Of Application For Seeking Re-Classification From The Promoter And Promoter Group Category To Public CategoryJun 25, 2025
Announcement under Regulation 30 (LODR)-Award_of_Order_Receipt_of_OrderJun 25, 2025
Disclosure Of Key Performance Indicators (Kpis) Under The SEBI (Issue Of Capital And Disclosure Requirements) Regulations 2018Jun 21, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media Release (Revised)Jun 21, 2025
Intimation Under Regulation 31A Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 - Outcome Of The Meeting Of The Board Of Directors Considering Requests For Re-Classification From The Promoter And Promoter Group Category To PJun 21, 2025
Announcement under Regulation 30 (LODR)-AcquisitionJun 21, 2025
Announcement under Regulation 30 (LODR)-AcquisitionJun 21, 2025
Board Meeting Outcome for Outcome Of Board Meeting Held On June 21 2025Jun 21, 2025
Outcome Of Board Meeting Held On June 21 2025Jun 21, 2025
Intimation Under Regulation 31A Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 - Receipt Of Requests For Re-Classification From The Promoter And Promoter Group Category To Public CategoryJun 19, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJun 18, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJun 18, 2025
Announcement under Regulation 30 (LODR)-Updates on AcquisitionJun 17, 2025
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSJun 12, 2025
Announcement under Regulation 30 (LODR)-Change in ManagementJun 03, 2025
Announcement under Regulation 30 (LODR)-AcquisitionJun 02, 2025
Announcement under Regulation 30 (LODR)-Earnings Call TranscriptMay 28, 2025
Compliances-Reg.24(A)-Annual Secretarial ComplianceMay 27, 2025
Clarification On Volume Movement LetterMay 27, 2025
Clarification sought from Emcure Pharmaceuticals LtdMay 27, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationMay 23, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeMay 22, 2025
Announcement under Regulation 30 (LODR)-Code of Conduct under SEBI (PIT) Regulations 2015May 22, 2025
Announcement under Regulation 30 (LODR)-AcquisitionMay 22, 2025
Appointment Of Secretarial AuditorMay 22, 2025
Announcement under Regulation 30 (LODR)-Change in ManagementMay 22, 2025
Audited Financial Results For The Quarter And Year Ended March 31 2025May 22, 2025
Corporate Action-Board approves DividendMay 22, 2025
Board Meeting Outcome for Outcome Of Board Meeting Held On May 22 2025May 22, 2025

Technical Indicators

RSI(14)
Neutral
42.67
ATR(14)
Less Volatile
43.67
STOCH(9,6)
Oversold
6.62
STOCH RSI(14)
Oversold
5.30
MACD(12,26)
Bearish
-14.69
ADX(14)
Weak Trend
18.53
UO(9)
Bearish
32.51
ROC(12)
Downtrend And Accelerating
-6.52
WillR(14)
Oversold
-90.94

Mutual Fund Holdings

Funding HouseCurrent Holding %1M Change1M Change %3M Change %Last 6M Trend
Aditya Birla Sun Life ELSS Tax Saver Direct-Growth
0.00%
-1055602
-0.96%
-0.37%
Nippon India Multi Cap Fund Direct-Growth
0.00%
-1000000
-0.31%
-0.29%
Nippon India Pharma Fund Direct-Growth
0.00%
-470272
-0.76%
-0.71%
ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Direct - Growth
0.00%
-450000
-1.04%
0.00%
Aditya Birla Sun Life Multi-Cap Fund Direct-Growth
0.00%
-439742
-0.95%
0.00%
DSP Healthcare Fund Direct - Growth
0.00%
-393289
-1.74%
-1.45%
DSP Aggressive Hybrid Fund Direct-Growth
0.00%
-308793
-0.38%
0.00%
Aditya Birla Sun Life Large & Mid Cap Fund Direct -Growth
0.00%
-275555
-0.68%
-0.60%
Bandhan Small Cap Fund Direct-Growth
0.00%
-253129
-0.25%
-0.22%
Aditya Birla Sun Life Small Cap Fund Direct-Growth
0.00%
-209774
-0.59%
0.00%
DSP Top 100 Equity Direct Plan-Growth
0.00%
-193759
-0.43%
0.00%
Aditya Birla Sun Life Pharma & Healthcare Fund Direct-Growth
0.00%
-177757
-2.87%
-2.74%
Axis Business Cycles Fund Direct-Growth
0.00%
-164565
-0.99%
-0.87%
Nippon India Retirement Fund - Wealth Creation Scheme Direct-Growth
0.00%
-128677
-0.56%
-0.51%
DSP Multicap Fund Direct - Growth
0.00%
-126385
-0.73%
0.00%
UTI Healthcare Fund Direct-Growth
0.00%
-124602
-1.53%
-0.82%
Bajaj Finserv Flexi Cap Fund Direct-Growth
0.00%
-116108
-0.31%
-0.74%
Aditya Birla Sun Life Bal Bhavishya Yojna Direct-Growth
0.00%
-99574
-1.23%
-1.12%
HDFC Dividend Yield Fund Direct - Growth
0.00%
-99204
-0.22%
-0.19%
Bajaj Finserv Healthcare Fund Direct-Growth
0.00%
-82002
-3.39%
-3.19%
HDFC Balanced Advantage Fund Direct-Growth
0.00%
-81119
-0.01%
-0.01%
Edelweiss Recently Listed IPO Fund Direct-Growth
0.00%
-79345
-1.22%
-1.32%
Axis Balanced Advantage Fund Direct-Growth
0.00%
-51116
-0.21%
-0.20%
WhiteOak Capital Pharma and Healthcare Fund Direct - Growth
0.00%
-50175
-1.73%
-1.99%
Aditya Birla Sun Life Retirement Fund - The 30s Plan Direct-Growth
0.00%
-32856
-1.13%
-1.02%

About Emcure Pharmaceuticals

Emcure Pharmaceuticals Limited is an Indian pharmaceutical company founded in 1981. It develops, manufactures, and globally markets pharmaceutical products across various therapeutic areas. The company operates 13 manufacturing facilities in India and has a presence in over 70 countries, with a strong focus on India, Europe, and Canada. Emcure specializes in orals, injectables, and biotherapeutics, covering areas such as gynecology, cardiovascular, vitamins, minerals, nutrients, HIV antivirals, blood-related, and oncology treatments. The company has a portfolio of differentiated products, including chiral molecules, complex APIs, biologics, and novel drug delivery systems. Emcure has commercialized six in-house manufactured biologics and holds patents for specific treatments. The company expanded through mergers, acquisitions, and establishment of new facilities over the years. In July 2024, Emcure launched an Initial Public Offer.
Listing Date
10 Jul, 2024(1 Years, -3 days)
Chairperson NameBerjis M Desai